EU Approves AZN Etcamah for ESR1 Breast Cancer; FDA Pending

The European Commission approved AstraZeneca’s (AZN) Etcamah (camizestrant) on July 23, 2026, for first-line treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer in patients whose tumors develop an emergent ESR1 mutation during endocrine therapy. The approval pairs camizestrant with any of the three approved CDK4/6 inhibitors: palbociclib (Ibrance), ribociclib (Kisqali), or abemaciclib (Verzenio).

Etcamah is the 11th new AstraZeneca medicine of the 20 the company expects to launch by 2030. AZN closed at $169.26 on July 24, with a market capitalization of roughly $262.5 billion.

The SERENA-6 data

The approval rests on the Phase 3 SERENA-6 trial, the first registrational study to use a ctDNA-guided approach in first-line breast cancer. Patients were monitored via blood test every 2 to 3 months. When an ESR1 mutation emerged without disease progression, patients were randomized to switch to camizestrant or continue the aromatase inhibitor, both maintaining the same CDK4/6 inhibitor.

At a planned interim analysis, 157 patients who switched to camizestrant achieved median PFS of 16.0 months (95% CI, 12.7 to 18.2) versus 9.2 months for 158 patients who continued the AI plus CDK4/6 inhibitor. That is a 56% reduction in the risk of disease progression or death (hazard ratio 0.44; p<0.00001). A subsequent analysis showed a statistically significant PFS2 benefit of 25.7 months. Overall survival data remain immature but trended in favor of camizestrant (HR 0.87).

What ESR1 mutation switching means

ESR1 mutations are the most common mechanism of acquired endocrine resistance in ER-positive breast cancer, arising in roughly 30% of patients on aromatase inhibitor therapy before disease progression. Historically, oncologists waited for radiographic progression before switching therapy. SERENA-6 tested a different premise: detect the resistance mutation in the blood before visible progression, then swap the endocrine agent while keeping the CDK4/6 backbone.

Camizestrant is a next-generation oral SERD and complete ER antagonist. Unlike fulvestrant, which requires intramuscular injection, camizestrant is a once-daily oral pill at 75 mg that degrades both wild-type and mutant estrogen receptors.

The US regulatory split

The US FDA is not yet on board. On April 30, 2026, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6 to 3 against camizestrant’s benefit-risk profile. The FDA extended the PDUFA date to December 2026 to review updated SERENA-6 results. The EU approval, along with prior approvals in Japan, the UAE, and Saudi Arabia, puts regulatory pressure on the FDA but does not bind it.

For readers tracking FDA decision deadlines, see our guide to PDUFA dates.

Competitive positioning

The first-line ER-positive, HER2-negative breast cancer market is dominated by CDK4/6 inhibitors paired with endocrine therapy. Pfizer’s Ibrance, Novartis’s Kisqali, and Lilly’s Verzenio collectively generate over $13 billion in annual revenue. Camizestrant complements them, approved alongside any of the three. The opportunity is the roughly 30% of patients who develop ESR1 mutations on AI therapy.

AstraZeneca’s breast cancer franchise already includes Enhertu, the HER2-directed ADC partnered with Daiichi Sankyo. Etcamah broadens it into endocrine resistance.

Risks

The December 2026 FDA decision is the primary risk. A second negative ODAC or a complete response letter would leave the US market closed. Overall survival remains immature. If the final OS fails to show a survival advantage, payer enthusiasm could wane. Competition from Elacestrant (Stemline), an oral SERD already approved for ESR1-mutated disease in later lines, limits the later-line opportunity.

What to watch next

The December 2026 FDA decision. If approved, camizestrant enters the US market as the first oral SERD for the mutation-switch first-line setting. If rejected, AstraZeneca still has ex-US revenue, but the largest market stays closed.

AstraZeneca press release | Onclive SERENA-6 coverage